SML2037
SR2595
≥98% (HPLC)
别名:
(S)-4′-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylic acid, 4′-[[5-[[[(1S)-1-[4-(1,1-Dimethylethyl)phenyl]ethyl]amino]carbonyl]-2,3-dimethyl-1H-indol-1-yl]methyl]-[1,1′-biphenyl]-2-carboxylic acid
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to faint brown
solubility
DMSO: 2 mg/mL, clear
shipped in
wet ice
storage temp.
−20°C
SMILES string
O=C(C(C=C1)=CC2=C1N(C(C)=C2C)CC(C=C3)=CC=C3C4=C(C(O)=O)C=CC=C4)N[C@H](C(C=C5)=CC=C5C(C)(C)C)C
InChI
1S/C37H38N2O3/c1-23-25(3)39(22-26-11-13-28(14-12-26)31-9-7-8-10-32(31)36(41)42)34-20-17-29(21-33(23)34)35(40)38-24(2)27-15-18-30(19-16-27)37(4,5)6/h7-21,24H,22H2,1-6H3,(H,38,40)(H,41,42)/t24-/m0/s1
InChI key
WKDKAVKAQXVFJV-DEOSSOPVSA-N
Biochem/physiol Actions
Inverse agonist of PPARγ that promoted osteogenic differentiation of isolated bone marrow-derived mesenchymal stem cells
SR2595 is an inverse agonist of PPARG (PPARγ) with an IC50 value of 30 nM. It was found to promote osteogenic differentiation of isolated bone marrow-derived mesenchymal stem cells accompanied by increased expression of bone morphogenetic proteins BMP2 and BMP6. SR2595 showed good pharmacokinetics and can be administered orally. It caused no significant change in insulin sensitivity, fasting insulin levels, food consumption or body weight when administered orally to mice.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable